New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual...
08 Novembre 2017 - 11:45PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to
announce the presentation of new data from its TACTI-mel Phase I
clinical trial in Australia investigating the use of eftilagimod
alpha (LAG-3Ig or IMP321), the Company’s lead product candidate, in
combination with pembrolizumab (KEYTRUDA) in unresectable or
metastatic melanoma patients.
The data will be presented in the poster titled “Pushing the
accelerator and releasing the brake: testing the soluble LAG-3
protein (IMP321), an antigen presenting cell activator, together
with pembrolizumab in unresectable or metastatic melanoma” (Poster
Number P259) for the first time at the Society for Immunotherapy of
Cancer (SITC) 2017 Annual Meeting, to be held on November 10-12,
2017 at the Gaylord National Hotel & Convention Center in
National Harbor, Maryland. Eftilagimod alpha, which is a soluble
LAG-3Ig fusion protein, is an APC activator boosting T cell
responses. “The data to be presented at the SITC meeting is very
encouraging and demonstrates that anti-tumor activity was observed
in patients following the administration of eftilagimod alpha in
combination with pembrolizumab. Furthermore, it is important
to note that prior to coming into this study, these patients were
treated with pembrolizumab monotherapy and did not achieve a
meaningful therapeutic benefit from this treatment,” stated Dr.
Frédéric Triebel, Prima’s Chief Scientific Officer and Medical
Officer.
The patients eligible to participate in the TACTI-mel Phase 1
clinical trial are those that have either had a suboptimal response
or had disease progression with KEYTRUDA monotherapy as a
first-line of treatment. 12 patients from the first two cohorts of
the trial were treated with 1 and 6mg doses of eftilagimod alpha
respectively. The third cohort of patients, being treated with 30
mg doses, is ongoing.
Dr. Frédéric Triebel further commented, “The data also supports
the hypothesis that there is a therapeutic synergy when
administering an APC activator, which enhances anti-tumor T cell
production, in combination with a checkpoint inhibitor, which
releases the brake on the T cells.”
The presentation at the SITC conference includes the following
results:
- Combination of eftilagimod alpha (1 and 6 mg) and pembrolizumab
in advanced metastatic melanoma patients is safe and well
tolerated;
- Anti-tumor activity (tumor reduction) was observed in 7/12
patients (58 %) in this study; prior to the study all of these
patients either had a suboptimal response or had disease
progression when treated with the pembrolizumab monotherapy;
- Data presented supports the hypothesis that combining an APC
activator (IMP321) with a checkpoint inhibitor (pembrolizumab)
results in a therapeutic synergy and a potential clinical benefit
over a checkpoint inhibitor monotherapy;
- Data presented supports further investigation of IMP321 in
combination with PD-1/ PD-L1 checkpoint inhibitors in different
tumor types.
Marc Voigt, Prima’s Chief Executive Officer, added, “We believe
the positive data, taken together with the excellent safety profile
of eftilagimod alpha and data from our ongoing clinical trial in
metastatic breast cancer, further validate the therapeutic utility
of modulating the LAG-3 immune control mechanism. We are very
pleased with the clinical progress of eftilagimod alpha and look
forward to presenting additional data from the TACTI-mel clinical
trial and exploring the potential therapeutic benefit of combining
it with other checkpoint inhibitors in other solid tumors.”
A copy of this SITC poster presentation is available on Prima’s
website in the Presentations section of the Investors tab at
http://primabiomed.com.au/investor/presentations.php
Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange (PRR) and on the NASDAQ (PBMD) in the US. For
further information please visit www.primabiomed.com.au.
For further information please
contact:
U.S. Investors:Jay Campbell, Vice President of
Business Development and Investor Relations, Prima Biomed+1 (917)
860-9404; jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646) 378-2933;
mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Set 2023 a Set 2024